Compare MTN & CRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTN | CRL |
|---|---|---|
| Founded | 1997 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 7.8B |
| IPO Year | 1997 | 2000 |
| Metric | MTN | CRL |
|---|---|---|
| Price | $134.89 | $160.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $173.17 | ★ $205.27 |
| AVG Volume (30 Days) | 819.7K | ★ 854.2K |
| Earning Date | 03-09-2026 | 02-18-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | ★ 17.26 | N/A |
| EPS | ★ 7.24 | N/A |
| Revenue | $2,975,101,000.00 | ★ $4,023,704,000.00 |
| Revenue This Year | $1.78 | N/A |
| Revenue Next Year | $3.98 | $1.70 |
| P/E Ratio | $18.91 | ★ N/A |
| Revenue Growth | ★ 3.06 | N/A |
| 52 Week Low | $126.16 | $91.86 |
| 52 Week High | $175.51 | $228.88 |
| Indicator | MTN | CRL |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 24.30 |
| Support Level | $136.29 | $148.34 |
| Resistance Level | $145.89 | $218.69 |
| Average True Range (ATR) | 4.84 | 9.40 |
| MACD | 0.64 | -6.28 |
| Stochastic Oscillator | 52.67 | 16.17 |
Vail Resorts Inc Bhd is a resorts and casinos company that operates mountain resorts and ski areas. The company has three business segments that include Mountain, Lodging, and Real Estate. The Mountain segment operates numerous ski resort properties that offer a variety of winter and summer activities, such as skiing, snowboarding, snowshoeing, hiking, and mountain biking. The Lodging segment owns and operates hotels and condominiums. The Real Estate segment owns, develops, and leases real estate, typically near its other properties. The company generates the vast majority of its revenue within the United States.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.